Anavex Life Sciences Corp (AVXL)

[biotechnician]

The graph clearly shows at 31 weeks a positive divergence from combo therapy. In fact even better than in earlier weeks. If this trend continues, mono therapy will be used in phase 3. It is my opinion that the SOC combo kept overall results down and led to the stabilization comments. But mono therapy could get exciting.